Q-omics provides the consensus-scored RPL22P2 profile across patient tissues and cancer cell-line models. RPL22P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL22P2 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, RPL22P2 RNA expression shows 13,405 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LUAD, and TGCT as cancer lineages where RPL22P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL22P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL22P2 survival associations across molecular data types. RPL22P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL22P2 RNA expression–survival associations across cancer types. High RPL22P2 expression shows unfavorable associations in LUAD, ACC and KIRC, but favorable associations in SKCM, HNSC and LUSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL22P2 RNA expression.
This table summarizes RPL22P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL22P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL22P2 shows lower tumor expression in PRAD and higher tumor expression in LUAD, THCA, COAD, HNSC and KIRC. The LUAD box plot shows higher RPL22P2 RNA expression in tumor versus normal tissue (log2 FC = +1.178, t-test p < 0.001).
This table shows molecular features associated with RPL22P2 in patient tissues and cancer cell lines. In patient samples, RPL22P2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
